GGHC
MAZE

Gilder Gagnon Howe & Co’s Maze Therapeutics MAZE Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$522K Sell
17,487
-5,795
-25% -$256K 0.01% 233
2025
Q4 		$965K Buy
+23,282
New +$800K 0.01% 219

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gilder Gagnon Howe & Co's MAZE Position: Q1 2026 in Review

Gilder Gagnon Howe & Co reduced its Maze Therapeutics (MAZE) stake by 25% in Q1 2026, selling an estimated $256K and leaving 17,487 shares worth $522K. The position accounts for 0.01% of the portfolio, ranked #233.

Gilder Gagnon Howe & Co first reported a position in MAZE in Q4 2025 and has held it in 2 quarters since. The position peaked at $965K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Gilder Gagnon Howe & Co held 17,487 shares of Maze Therapeutics worth $522K as of Q1 2026.
  • Gilder Gagnon Howe & Co sold 5,795 Maze Therapeutics shares in Q1 2026, an estimated $256K.
  • Maze Therapeutics made up 0.01% of Gilder Gagnon Howe & Co's portfolio in Q1 2026, its #233 holding.
  • Gilder Gagnon Howe & Co first reported a position in Maze Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Gilder Gagnon Howe & Co's Maze Therapeutics position peaked at $965K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.